This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
The efficacy of high dose and low dose Edoxaban, an oral factor Xa inhibitor, was compared to Warfarin in patients with high risk a-fib. The efficacy endpoint was stroke or systemic embolus, the safety endpoint was bleeding. Edoxaban was non-inferior to Warfarin for both doses in terms of efficacy, and was associated with reduced risks of bleeding and cardiovascular death.